

Addressing Modifiable Risk Factors for Gastric Cancer

Meira Epplein PhD

Co-Leader, Cancer Risk, Detection, and Interception, Duke Cancer Institute

Professor, Population Health Sciences and Medicine, Duke University

April 11, 2025



Duke Cancer Institute

Addressing Modifiable Risk Factors for Gastric Cancer

*Moving prevention from epidemiology to
the community and the clinic*

Meira Epplein PhD

Co-Leader, Cancer Risk, Detection, and Interception, Duke Cancer Institute

Professor, Population Health Sciences and Medicine, Duke University

April 11, 2025




Duke Cancer Institute

Gastric Cancer and Health Disparities

- Race is a social construct, and our team is opposed to the practice of race-based medicine
- Race-conscious research can help mitigate health inequities
- Our goal is to conduct translational research in diverse and inclusive cohorts that reflect our local community so that knowledge gained will be relevant and impactful for those most affected by gastric cancer
- Our research team is particularly interested in *H. pylori* eradication as a strategy to address gastric cancer disparities and translational approach for early gastric cancer interception

Stomach
Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2020
By Race/Ethnicity, Observed SEER Incidence Rate, Both Sexes, All Ages, All Stages





Marked disparities in gastric cancer incidence in the US

Locally, 24% of those presenting for endoscopy and 62% of those diagnosed with gastric cancer are Black patients


SEER Data accessed online October 2023. <https://seer.cancer.gov/statfacts/html/stomach.html>

Mortality differences in gastric cancer




Helicobacter pylori Disparities

***H. pylori* antibody prevalence by year of birth, in MEC, NYU WHS, PLCO, and SCCS (N = 4,476)**




***H. pylori* CagA antibody prevalence**



Varga, Butt et al., *Cancer Epidemiol Biomarkers Prev* 2020.

Helicobacter pylori Disparities

H. pylori VacA and CagA antibody levels by race
in the US among *H. pylori* sero-positives




Butt et al., *Cancer Causes and Control* 2020; 31:601-606.

DIGEST


Disparities in gastric cancer: Expanding our understanding of the underlying reasons

CagA antibody levels by race and cohort, non-cardia gastric cancer cases and matched controls



published; do not share

Helicobacter pylori in the Community



DISH

Durham Initiative for
Stomach Health

DISH Objectives

- To conduct a pilot study to determine prevalence of *H. pylori* and other stomach cancer risk factors in the Durham, NC community
- To engage and partner with community leaders to serve as advisors to ensure the benefit of increasing overall health and health knowledge in the local population
- To lay the groundwork for a **future multi-site prevention and eradication initiative**, to ultimately reduce the burden of stomach cancer among high-risk populations

Helicobacter pylori in the Community

	Initial project ideas	Final project processes	Impact of Study
Stakeholder meetings			
Input from health services & community-based researchers	One-on-one meetings with select faculty	Roundtable meeting with experts from community outreach to policy implementation	Group feedback enhanced a bigger-picture thinking of the overall goals, towards which the current project would be a first step
Input from community	Development of a steering comm.	Work with established community advisory councils	Capitalizing on already existing relationships with the community is pragmatic and feasible
Input from clinicians	Focus groups with clinicians	One-on-one meetings with clinicians	Scheduling one-on-one meetings with clinicians is more practical
Study planning			
How to approach potential study participants	Meet with church pastor	Meet with church pastor; present during Sunday services; meet with congregants	Importance of meeting the congregation and introducing the topic personally, and presenting the project as a cancer prevention strategy rather than focus on disparity
How to describe the study	Study flyer	Study flyer, study brochure, in-person meetings at the church to explain the project	Interacting with potential study participants in multiple ways allows for an iterative process to best share study information

Helicobacter pylori in the Community

	Initial project ideas	Final project processes	Impact of Study
Participant recruitment			
Location	Clinics	Community (at a local church)	Individuals are most comfortable at sites they frequent and trust
No. of events and sites	Multiple dates and sites	One-day event on site at one church	Scaling down to for ease of execution and assessment of logistics
Date and timing of event	Sunday after services	All-day Tuesday prior to evening services	Provides flexibility for potential participants
Consent	In-person consent	Electronic + in-person consent	To improve event logistics, make as many tasks available to be completed prior to the day of event as possible
Study event			
Questionnaire	Potentially relevant gastric cancer risk factors, plus detailed lifestyle variables	Shorten as much as possible - remove religiosity questions, but add questions to help think about long-term implementation	Participants need to feel that the questions are reasonable, not invasive (like religiosity questions), but that also get to the larger issues of beliefs/behavior, physician interaction, and finances
Biospecimen Collection	Breath test, blood draw, stool sample	Breath test and blood draw	The stool sample would not have added significantly more information, but would create an additional barrier to participation.

Helicobacter pylori in the Community

	Initial project ideas	Final project processes	Impact of Study
Study event			
Participant reimbursement	Amazon gift card	Walmart gift card plus boxed meal, social security number waiver received	Walmart was favored by this community; participation during lunch or dinner hour highlighted importance of boxed meal; requiring a social security number provides an additional barrier.
Follow-up			
Individual results	No return of individual results	Results mailed to participant with an accompanying phone call by study team within 2 weeks of study event	There is value and need to give back to participants. Follow-through includes: staff phone-calls to results, patient navigators provided to those with financial barriers, and physician executive summary to inform guideline-concordant H. pylori treatment.
Re-testing	No re-testing	Follow-up events at church to re-test after treatment	There is documented ~30% failure of H. pylori treatment to eradicate; re-testing allows us to re-visit the community, confirm eradication or to support seeking of salvage treatment.


Helicobacter pylori in the Community

DISH Study Event – May 15, 2018, 2-8pm at The River Church



- **92 individuals participated**, completing:
an extensive questionnaire, taking the breath test, and donating a blood sample
- **25% were found to be *H. pylori*+ by the breath test**
- Results were returned to individuals within 2 weeks, along with a physicians' executive summary including information on approved treatment
- 6-months post-event, on November 13, we did a follow-up visit at the church, where we re-tested on site, and returned results there

Helicobacter pylori in the Community



- 70% of those originally *H. pylori*+ who returned for follow-up had successfully eradicated the bacteria.
- Reasons for persistent infection include:
 - Prescribed the wrong therapy
 - Non-adherence to the full course of treatment
 - *H. pylori* antibiotic resistance to first-line therapy

Helicobacter pylori in the Community

DISH Follow-up

Personal Stories

- One participant has had stomach distress for years, including a hospital stay, where she was asked to take the breath test for *H. pylori*, but she refused.
- After our church engagement, testing, and recommendations, she eradicated her *H. pylori* and feels significantly better.



Helicobacter pylori in the Community

DISH Follow-up

Personal Stories



- One participant we determined to have a persistent infection met with their physician who decided to perform an endoscopy and found multiple ulcers. The physician also sent the tissue to be tested for antibiotic resistance. The results show the participant was resistant to clarithromycin. Because of this, quadruple therapy was prescribed.
- The most recent endoscopy showed the ulcers are healing and the patient has cleared her *H. pylori* infection.

Helicobacter pylori in the Community

Partnership with Bishop Ronald Godbee, Pastor of the River Church



DISH STUDY RESULTS

Duke Cancer Institute



Thank you for participating!

We want to thank you for participating in the **DISH** study about the bacteria *Helicobacter pylori* (*H. pylori*) in Durham! We cannot do research like this without partners like you who help to advance science and build healthy communities.

What We Wanted To Know

We wanted to find out how many people in our community are infected with *H. pylori*, and how to help them seek treatment. Infection often has no symptoms, and most people with *H. pylori* don't know they have it. But, it is the main cause of stomach cancer in America. Stomach cancer is the #6 cause of cancer deaths in Black men. The good news is that *H. pylori* is easy to treat (2 weeks of antibiotics + a proton pump inhibitor like Prilosec). Getting rid of *H. pylori* lowers the risk of getting stomach cancer by 50%. Identifying and treating people with it can save countless lives.



Questions? Please contact the **DISH** study team at 919-681-4762 or DISH@duke.edu.

Duke Cancer Institute

DISH Study Results

Who Was In The Study



92 Volunteers



Average Age: 54

Everyone who joined the study:

- Filled out a questionnaire
- Gave a blood sample
- Did a breath test for *H. pylori*

All participants enrolled in the **DISH** study at The River Church in Durham, NC on May 15, 2018.



What These Results Mean

- If the test result we mailed to you was negative, it means you don't have *H. pylori*.
- 1 out of every 4 people in our study was positive for *H. pylori* and referred for treatment.
- Most people only need 1 round of treatment to clear the infection, but about 30% of people will need more.



Our Next Steps

We shared this information with Duke doctors and healthcare providers. These providers have told us that they will engage in more discussion about *H. pylori* and treatment with their patients. In addition, more follow-up testing will be done after treatment to confirm that an infection is cleared. If the infection is still there after treatment, then additional treatment (as well as procedures, if appropriate) will be done until a patient tests negative.

Special thanks to Bishop Ronald L. Godbee and the congregation of The River Church

Helicobacter pylori in the Community


STASH

SUPPORTING TRIBAL STOMACH HEALTH

Screen for *H. pylori* Infection to Reduce Your Risk of Developing Stomach Cancer!

Who is Eligible?

- Age 18+
- Speak fluent English.
- **No** prior gastric surgery
- **No** prior gastric cancer
- **No** use of antibiotics, Pepto Bismol, or any proton pump inhibitor in the 2 weeks prior to enrollment.




What to Expect?

- Up to 1 hour of time
- A general questionnaire
- An *H. pylori* infection breath test
 - **No** eating or drinking 1 hour before taking the test
 - Participants will receive the results of their test
 - Follow-up survey
- \$25 gift card incentive

When and Where?

- 12 pm on January 18th, 2024
- Lumbee Tribe Cultural Center

638 Terry Sanford Dr,
Maxton, NC 28364



SOUTHEASTERN
AMERICAN INDIAN
CANCER HEALTH EQUITY
PARTNERSHIP
(SAICEP)

A CDC LABORATORY NETWORK

UNCC | UNIVERSITY OF NORTH CAROLINA | CHS | DUKES UNIVERSITY

Please sign up by calling:
Mr. Reggie Brewer
Phone: 910 405 9114

Protocol No. Pro0011767



Helicobacter pylori in the Clinic

grace
*gastric immune response and
cancer interception*


A GI Tissue Repository Study

GRACE Team

DCI Core Partners



Shannon McCall
Biospecimen



Donna Niedzwiecki
Biostatistics

GRACE Trainees



Katie Garman
PI



Meira Epplein
PI



Nina Salama
Site PI, FHCRC



Sydnee Crankshaw
Program Manager



Anna Diocareza
Lead CRC



Amanda Mandy
CRC



Paula Scotland
Lab analyst II



Priya Alagenan
3rd/4th year
med student



Hannah Brown
Internal medicine
resident



Danielle Mebuge
Pediatric GI
fellow




Grace Sekaya
DIRECT Fellow
gap year trainee




Caroline Labriola
3rd year
med student



Rachel Zuzul
3rd year
med student



Allison Taylor
Hem/Onc
fellow



Jacqueline Emerson
3rd/4th year
med student



Serach Patterson
DIRECT Fellow
gap year trainee




Angel Hailemariam
DIRECT Fellow
gap year trainee



Lucas Collins
3rd year
med student


Helicobacter pylori in the Clinic

The Correa Cascade of gastric carcinogenesis



Helicobacter pylori in the Clinic

The Correa Cascade of gastric carcinogenesis




Creating a New Translational Research Cohort

- To develop new strategies for cancer interception and treatment, **basic/translational cohorts should reflect the demographics of those affected by the disease.**
- Research activities, such as designing studies, developing surveys, recruiting and enrolling patients, offer opportunities for partnership with research participants.

How can we build deeper trust of translational research and achieve new advances in gastric cancer? Our goal was to generate a new diverse and inclusive cohort to understand factors underlying health disparities in gastric cancer and to generate an inclusive set of pre-cancer gastric organoids to develop novel approaches for personalized cancer interception.

Factors affecting Gastric Cancer Disparities in the US




Systemic Racism and related socioeconomic factors may impact several areas across this continuum as well as willingness to participate in research.

grace

*gastric immune response and
cancer interception*

A GI Tissue Repository Study




Helicobacter pylori in the Clinic

H. pylori Testing and Treatment and Gastric Cancer Survival

	Hazards Ratio ^a	95% CI	P-value
Ever tested for <i>H. pylori</i> prior to or at cancer diagnosis?			
Never	1.00	(ref)	
Tested positive and treated <1 year prior to or at cancer diagnosis	0.21	0.08-0.58	0.003
Tested positive and treated ≥1 year prior to diagnosis	0.45	0.18-1.11	0.08
Tested positive and not treated	2.01	0.55-7.38	0.30
Tested negative	0.49	0.24-1.00	0.05
Age (per one year increase)	1.00	0.98-1.03	0.96
Self-reported race (ref: white)			
Black	1.17	0.66-2.08	0.58
Insurance (ref: private)			
Medicare	0.57	0.28-1.13	0.11
Other	0.93	0.42-2.06	0.86
Treatment			
No chemotherapy	2.21	1.00-4.86	0.05
No radiation	1.02	0.53-1.95	0.96
No neoadjuvant treatment	2.22	1.07-4.60	0.03
AJCC 8 stage (ref: I & II)			
Stage III	6.83	2.24-20.88	0.0007
Stage IV	13.83	5.88-32.55	<0.0001
Stage missing	17.90	5.68-56.42	<0.0001

Helicobacter pylori in the Clinic


Stage IV Gastric Cancer - Survival by *Hp* Treatment Status




grace

*gastric immune response and
cancer interception*

A GI Tissue Repository Study




INTENTIONAL INCLUSION ACROSS ALL ASPECTS OF RECRUITMENT




Black patients comprise 24% of those presenting for endoscopy, 47% of screening group, 49% of those approached for enrollment and 46% of participants enrolled in the prospective cohort.

Self-Reported Survey Data in Enrolled Participants: Racial Discrimination by Sector – 34% in Healthcare Setting



ACEs and Self-Reported Gastric Symptoms



Key concepts for inclusion in clinical research

Intentionality – *Planning and Screening, and Enrollment*

Bi-directional community engagement – *Prioritization of Research Questions, Recruitment Strategies, Survey development*

Outreach – *Community Events, Partnership, Accessibility*

Trustworthiness – *Recognizing past, Listening and ensuring Participants feel heard, Answer all Questions*

Integrity – *Best research practices and scientific rigor*

Transparency – *Clear communication*

Return of results – *Critically Important aspect of Trustworthiness and Partnership - Share Gratitude and Clinical Relevance*

Ref: Washington V et al. Clin Pharmacol Ther (2023) 113:575-584.

Thank you!

GRACE team

Katie Garman
Nina Salama
Sydnee Crankshaw
Anna Diocareza
Amanda Mandy
Priya Alagesan
HannahSofia Brown
Danielle Mebuge
Grace Sekaya
Caroline Labriola
Rachel Zuzul
Allison Taylor
Jacqueline Emerson
Serach Patterson
Angel Hailemariam
Lucas Collins
Shannon McCall
Donna Niedzwiecki

DUKE UNIVERSITY

Duke Cancer Institute

Steve Patierno
Mike Kastan
Sydnee Crankshaw
Yadu Raveendran
Tomi Akinyemiju
Aretha Rice
Angelo Moore

Pathology
Shannon McCall
Will Jeck

Population Health Sciences

Jennifer Gierisch
Kevin Weinfurt
Leah Zullig
Kathryn Pollak

VANDERBILT

Epidemiology

Bill Blot
Martha Shrubsole
Hui Cai
Wei Zheng
Matt Varga

Gastroenterology

Rick Peek
Pelayo Correa
Tim Cover

JEFFERSON UNIV.

Terry Hyslop
Yutong Li

FRED HUTCH

John Potter
Nina Salama
Lesley Tinker

UNIVERSITY OF HAWAII

Loic Le Marchand
Lynne Wilkens
Kami White

UNC – Chapel Hill

Ronnie Bell
Ryan Dial

RUTGERS

Haejin In

GERMAN CANCER RESEARCH CENTER

Michael Pawlita
Julia Butt
Tim Waterboer

HARVARD

Mingyang Song
Howie Sesso

NCI, NIH

Gwen Murphy
Christian Abnet
Phil Taylor
Allan Hildesheim
Sonja Berndt
Tram Lam

AMERICAN CANCER SOCIETY

Lauren Teras

ALBERT EINSTEIN UNIVERSITY

Sylvia Smoller
Gloria Ho

NYU

Yu Chen

JOHNS HOPKINS

Kala Visvanathan

THE RIVER CHURCH

Bishop Ronald Godbee

Valarie Worthy

All of the wonderful congregation members who supported and participated in DISH

SAICEP

Ronny Bell, Ryan Dial

All of the wonderful NC tribal members who supported and participated in STASH

FUNDING

National Cancer Institute, NIH

R01 CA267842 (Epplein PI)
P20 CA251657 (Patierno PI)
R01 CA190428 (Epplein PI)
R01 CA174853 (Epplein PI)
K07 CA151782 (Epplein PI)

Duke Cancer Institute